Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 40, 2010 - Issue 9
2,062
Views
87
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds

, , , , , , , , , & show all
Pages 637-649 | Received 30 Apr 2010, Accepted 08 Jun 2010, Published online: 12 Jul 2010
 

Abstract

  1. We compare three different approaches to scale clearance (CL) from human hepatocyte and microsome CLint (intrinsic CL) for 52 drug compounds.

  2. By using the well-stirred model with protein binding included only 11% and 30% of the compounds were predicted within 2-fold and the average absolute fold errors (AAFE) for the predictions were 5.9 and 4.1 for hepatocytes and microsomes, respectively.

  3. When predictions were performed without protein binding, 59% of the compounds were predicted within 2-fold using either hepatocytes or microsomes and the AAFE was 2.2 and 2.3, respectively.

  4. For hepatocytes and microsomes there were significant correlations (P = 8.7 × 10−13, R2 = 0.72; P = 2.8 × 10−9, R2 = 0.61) between predicted CLint in vivo (obtained from in vitro CLint) and measured CLint in vivo (obtained using the well-stirred model). When CL was calculated from the regression, 76% and 70% of the compounds were predicted within 2-fold and the AAFE was 1.6 and 1.8 for hepatocytes and microsomes, respectively. We demonstrate that microsomes and hepatocytes are in many cases comparable when scaling of CL is performed from regression.

  5. By using the hepatocyte regression, CL for 82% of the compounds in an independent test set (n = 11) were predicted within 2-fold (AAFE 1.4). We suggest that a regression line that adjusts for systematic under-predictions should be the first-hand choice for scaling of CL.

Acknowledgements

The authors greatly acknowledge Dr Urban Fagerholm at Clinical Pharmacology & DMPK, AstraZeneca R&D Södertälje, Sweden, for valuable comments and advice, and Dr Suzanne Iverson at Clinical Pharmacology & DMPK AstraZeneca R&D Södertälje, Sweden, for reviewing the manuscript.

Declaration of interest

The authors report no conflicts of interests. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.